Muscle invasive bladder cancer Cancer Malignant neoplasm of bladder
Conditions
Interventions
A prospective phase II study clinically implementing adaptive planning in radiotherapy for bladder cancer. All eligible patients will be treated with new clinical protocol.
All patien
Sponsors
Institute of Cancer Research (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged greater than 18 years, either sex 2. Histologically confirmed invasive carcinoma of the bladder 3. Patient planned to receive hypofractionated radiotherapy to the bladder 4. No previous pelvic radiotherapy 5. Written informed consent given according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) and national/local regulations
Exclusion criteria
Exclusion criteria: Urinary catheter in-situ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Appropriate identification and correction of fractions requiring adaptive planning, assessed at the end of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of fractions requiring adaptive planning, assessed at end of treatment 2. Dose-volume histogram (DVH) analysis of CTV coverage using anisotropic margins, assessed at end of treatment 3. Time to local disease progression, measured at 2 years 4. Overall survival, measured at 2 years | — |
Countries
United Kingdom
Outcome results
None listed